NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: A case story in medicinal inorganic chemistry

E Alessio, L Messori - Molecules, 2019 - mdpi.com
NAMI-A ((ImH)[trans-RuCl4 (dmso-S)(Im)], Im= imidazole) and KP1019/1339
(KP1019=(IndH)[trans-RuCl4 (Ind) 2], Ind= indazole; KP1339= Na [trans-RuCl4 (Ind) 2]) are …

The development of ruthenium (II) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications

FE Poynton, SA Bright, S Blasco, DC Williams… - Chemical Society …, 2017 - pubs.rsc.org
Ruthenium (II)[Ru (II)] polypyridyl complexes have been the focus of intense investigations
since work began exploring their supramolecular interactions with DNA. In recent years …

Thirty years of the drug candidate NAMI‐A and the myths in the field of ruthenium anticancer compounds: a personal perspective

E Alessio - European Journal of Inorganic Chemistry, 2017 - Wiley Online Library
As anticipated in the title, this contribution is basically divided into two, strictly connected,
parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 …

Synthesis, characterization, crystal structure, DNA and HSA Interactions, and anticancer activity of a mononuclear Cu (II) complex with a Schiff base ligand containing …

SU Parsekar, K Paliwal, P Haldar, PKS Antharjanam… - ACS …, 2022 - ACS Publications
A mononuclear Cu (II) complex [Cu (HL)(o-phen)]· H2O (1)[H3L=, o-phen= 1, 10-
phenanthroline] was isolated from methanol, and its X-ray single-crystal structure was …

Molecular mode of action of NKP-1339–a clinically investigated ruthenium-based drug–involves ER-and ROS-related effects in colon carcinoma cell lines

LS Flocke, R Trondl, MA Jakupec, BK Keppler - Investigational new drugs, 2016 - Springer
Abstract Sodium trans-[tetrachloridobis (1 H-indazole) ruthenate (III)](NKP-1339) is a
clinically investigated ruthenium-based metal complex, which shows promising results in …

X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding …

A Bijelic, S Theiner, BK Keppler… - Journal of medicinal …, 2016 - ACS Publications
Ruthenium (III) complexes are promising candidates for anticancer drugs, especially the
clinically studied indazolium trans-[tetrachlorobis (1 H-indazole) ruthenate (III)](KP1019) and …

Mechanisms of action of Ru (II) polypyridyl complexes in living cells upon light irradiation

M Jakubaszek, B Goud, S Ferrari… - Chemical communications, 2018 - pubs.rsc.org
The unique photophysical properties of Ru (II) polypyridyl complexes make them very
attractive candidates as photosensitisers in Photodynamic Therapy (PDT). However, to date …

A ruthenium(ii) based photosensitizer and transferrin complexes enhance photo-physical properties, cell uptake, and photodynamic therapy safety and efficacy

P Kaspler, S Lazic, S Forward, Y Arenas… - Photochemical & …, 2016 - Springer
Metal-based photosensitizers are of interest as their absorption and chemical binding
properties can be modified via the use of different ligands. Ru 2+ based photosensitizers are …

Novel and versatile imine-N-heterocyclic carbene half-sandwich iridium (III) complexes as lysosome-targeted anticancer agents

Y Yang, L Guo, Z Tian, Y Gong, H Zheng… - Inorganic …, 2018 - ACS Publications
We, herein, report the synthesis, characterization, luminescence properties, anticancer, and
antibacterial activities of a family of novel half-sandwich iridium (III) complexes of the general …

Anticancer ruthenium (III) complexes and Ru (III)-containing nanoformulations: An update on the mechanism of action and biological activity

C Riccardi, D Musumeci, M Trifuoggi, C Irace… - Pharmaceuticals, 2019 - mdpi.com
The great advances in the studies on metal complexes for the treatment of different cancer
forms, starting from the pioneering works on platinum derivatives, have fostered an …